

ColoSTAT[®] Access Program Gains Momentum with Leading Clinician Adoption

Highlights

- **ColoSTAT[®] Clinical Access Program reaches 16 enrolled clinicians across Australia**
- **Program supports commercial adoption, physician engagement and collection of real-world clinical utilisation data**
- **Senior gastroenterologists and surgeons have been attracted to the Program, reinforcing growing clinical confidence in ColoSTAT[®]**
- **The Program is designed to strengthen ColoSTAT[®]'s positioning as a triage tool for symptomatic colorectal cancer patients**

Melbourne, Australia, 26th May 2026: Rhythm Biosciences Ltd (ASX: RHY) is pleased to provide an update on the continued expansion of the ColoSTAT[®] Clinical Access Program (Program), with 16 clinicians now enrolled across key Australian healthcare centres. The Program is designed to complement routine sales by generating real-world evidence to support future reimbursement pathways, clinician adoption, and broader commercialisation activities for ColoSTAT[®], Rhythm's blood-based colorectal cancer triage test.

Program Overview and Participant Profile

The ColoSTAT[®] Clinical Access Program was established to enable clinicians across Australia to incorporate ColoSTAT[®] into their clinical practice while contributing structured real-world data to support the test's growing clinical evidence base. The Program provides participating clinicians with access to ColoSTAT[®] testing, clinical support materials, and a framework for structured data collection and feedback.

The Program has now reached 16 enrolled participants, with enrolment continuing across additional healthcare centres and specialist networks. Importantly, the Program is attracting senior clinicians - a strong indicator of growing confidence in the clinical utility and potential application of ColoSTAT[®]. Participants represent a diverse range of specialist backgrounds, including gastroenterologists and surgeons, across both private and public health sectors, highlighting the broad applicability of ColoSTAT[®] across the colorectal cancer diagnostic pathway. The participants have been enrolled from key geographies

including Sydney, Melbourne, Brisbane and the surrounding metropolitan areas. The Program operates in addition to routine ColoSTAT® sales.

The engagement of senior clinicians across multiple geographies and specialities represents meaningful validation of ColoSTAT®'s clinical relevance and growing market traction.

Rhythm Biosciences expects enrolment to continue building in the coming months as awareness of the Program expands within the clinical community.

Generating Real-World Evidence

The Strategic Value of Real-World Evidence

Real-world evidence (RWE) is increasingly recognised by payers, health technology assessment bodies, hospital networks and clinical guideline developers as an important component in the evaluation of emerging diagnostic technologies. Unlike controlled clinical trial data, RWE captures the performance, utility and integration of a test in everyday clinical practice across a diverse range of patients, clinicians, and healthcare environments.

For ColoSTAT®, the Access Program provides a structured mechanism to generate real-world clinical data within Australian healthcare settings. Data collected through the Program - including clinician experience, patient profiles, clinical workflows, and test outcomes – is expected to play an important role in demonstrating ColoSTAT®'s clinical utility, workflow integration potential and broader value proposition to hospitals, health networks, insurers, and ultimately government reimbursement authorities.

The involvement of senior clinicians in the Program is particularly significant. Experienced specialists are typically selective in adopting new diagnostic technologies, and their participation reflects a growing confidence in both the science underpinning ColoSTAT® and its potential to address a recognised unmet need in colorectal cancer triage.

The Access Program represents a disciplined and cost-effective approach to expanding the clinical and commercial foundation for ColoSTAT® ahead of broader market access, reimbursement discussions, and future adoption initiatives.

Program Outlook

Rhythm Biosciences will continue to actively enrol participants into the ColoSTAT® Clinical Access Program and expects participation to expand over the coming months as awareness and engagement within the clinical community continue to build. The Company intends to provide further updates on Program progress, and over time, insights from the real-world clinical data being generated through the Program.

The Company's focus remains on generating credible, structured clinical data that strengthens ColoSTAT®'s long-term commercial positioning and supports future reimbursement pathways, broader clinical adoption, and potential inclusion in clinical guidelines.

CEO Commentary

Rhythm Biosciences CEO & Managing Director, Dr David Atkins, said:

“Reaching 16 enrolled participants in the ColoSTAT® Access Program is a meaningful milestone for the Company and an important indicator of growing clinical engagement with ColoSTAT®. The calibre of clinicians who have joined the Program - including senior gastroenterologists and surgeons - reflects increasing confidence in ColoSTAT® as a practical frontline triage tool for symptomatic patients.

The Access Program is doing exactly what it was designed to do: placing ColoSTAT® in the hands of experienced clinicians, generating structured real-world evidence, and building the clinical foundations required for broader commercial adoption. Importantly, programs such as this are a critical step in the pathway toward reimbursement discussions, clinical guideline inclusion, and long-term market penetration.

As with many diagnostic technologies, meaningful commercial adoption takes time and requires strong clinical validation and engagement from healthcare professionals. We are encouraged by the momentum we are seeing through the Program and believe these early indicators position the Company well for its next phase of growth.

We look forward to reporting further progress on enrolment and, over time, sharing insights from the data being generated through the Program.”

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.